Venrock Adviser, Llc

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$2.68B
Q ending 2026-03-31
Prior quarter
$2.02B
Q ending 2025-12-31
Change
+32.3% QoQ · +128.0% YoY
Positions
33
reported holdings

Largest positions

All 33 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
Apogee Therapeutics IncAPGEShares$714.9M8.5M
Erasca IncERASShares$265.1M16.4M
Oruka Therapeutics IncORKAShares$203.5M4.1M
Spyre Therapeutics IncSYREShares$185.9M3.7M
Kalvista Pharmaceuticals Inc4XC1Shares$130.3M6.5M
Dianthus Therapeutics IncDNTHShares$99.0M1.2M
Damora Therapeutics IncDMRAShares$93.3M3.6M
Ocular Therapeutix IncOCULShares$87.6M10.3M
Cogent Biosciences IncCOGTShares$77.0M2.0M
Viridian Therapeutics IncVRDNShares$75.9M3.9M
Savara IncSVRAShares$75.0M13.7M
Enliven Therapeutics IncELVNShares$67.7M1.7M
Oric Pharmaceuticals IncORICShares$54.7M4.3M
Vor Biopharma IncVORShares$54.3M3.0M
Maze Therapeutics IncMAZEShares$47.8M1.6M
Cytomx Therapeutics IncCTMXShares$46.9M10.0M
Jade Biosciences IncJBIOShares$45.2M3.2M
Dyne Therapeutics IncDYNShares$39.4M2.2M
Crescent Biopharma Inc.Shares$39.2M2.1M
Zura Bio LtdShares$38.3M6.4M
Relmada Therapeutics IncRLMDShares$33.7M4.8M
Engene Holdings IncShares$32.5M4.8M
Tenax Therapeutics IncTENXShares$26.8M1.7M
Adlai Nortye LtdANLShares$22.2M3.2M
Century Therapeutics IncIPSCShares$19.7M8.7M
Cullinan Therapeutics IncCGEMShares$19.6M1.4M
Cybin IncHELPShares$18.5M3.9M
Surrozen IncSRZNShares$18.4M633K
Septerna IncSEPNShares$12.2M506K
Korro Bio IncKRROShares$11.4M1.0M
Alto Neuroscience IncANROShares$11.2M500K
Artiva Biotherapeutics IncARTVShares$10.4M1.6M
X4 Pharmaceuticals IncXFORShares$1.4M331K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.